Investing in innovative approaches to transform how drugs are developed

Investing in innovative approaches to transform how drugs are developed

Imagine dedicating years or even decades of your life to a project with the hope that it could change people’s lives, only to find out in the end that your concept doesn’t work... That’s what it’s like to work in pharmaceutical R&D. For every 10 investigational medicines that enter human trials, on average, only one will result in an approved medicine. 

Read More

Six new companies in two years...

Six new companies in two years...

...That’s what happens when pharma and venture capitalists work together.

The way pharmaceutical companies find new drugs is changing. Collaboration with universities, biotechs and venture capital firms is key to bringing new innovative medicines to patients. Today we announced that we have launched three new companies as part of an ongoing collaboration with venture capital firm Avalon Ventures to fund and launch up to 10 early-stage life sciences companies. That brings the total to six new companies in two years.

Read More

Closing the gap: "Building Bridges" for better asthma care

Closing the gap: "Building Bridges" for better asthma care

On May 19, I was privileged to join top asthma bloggers, patient advocates, school nurses, and physicians at the GSK Asthma Summit in Denver, Colorado. Coinciding with Asthma Awareness Month, the GSK Asthma Summit focused on the issue of improving school-based asthma management and addressing asthma disparities in the inner cities of America.

Read More

Understanding the impact of lupus on patients’ lives

Understanding the impact of lupus on patients’ lives

It’s Lupus Awareness Month, a time when the lupus community comes together to draw attention to this rare, chronic, autoimmune disorder. Earlier this month, we had the pleasure of hosting more than one dozen lupus bloggers and patient advocacy groups for an in-person and virtual GSK lupus summit where we discussed issues facing the lupus community. 

Read More